1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Sepsis Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Sepsis Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • November 2021
  • 152 pages
  • ID: 6184950
  • Format: PDF
  • Mordor Intelligence LLP


Table of Contents

Search Inside

The sepsis diagnostics market was valued at USD 550 million in 2020 and is expected to reach USD 975 million in 2026 by registering the CAGR of 9.8% during the forecast period.

The coronavirus disease 2019 has proved to wreak havoc to health system leaders throughout the world. The healthcare systems across the world are witnessing an advanced health system stretched beyond its capacity. For instance, according to The Society of Critical Care Medicine, in late 2020 the outbreak of COVID-19 has generated a concern that critically ill patients may overwhelm existing ICU bed availability. If the infection curve is not flattened and the pandemic is concentrated in a 6-month period, that would leave a capacity gap of 1,373,248 inpatient beds and 295,350 ICU beds. This surge in hospital admission for the past year has increased the risk of hospital-acquired infection and the health providers are adopting all the protocols and tests to restrain the infection, which is expected to boost the market growth.

The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. As per the data published by the World Health Organization (WHO) in April 2018, sepsis affects more than 30 million people globally, and over 6 million deaths every year are caused by sepsis. As per the same data, around 3 million newborns and 1.2 million children suffer from this condition every year.

In the present scenario, most of the existing sepsis diagnostic tests can take up to 72 hours or more to process and provide results. Thus, there is a high unmet need for more efficient and rapid diagnostic tests in the market for early diagnosis of this life-threatening condition that could save thousands of lives. Also, there has been increase in regulatory approval and the introduction of technologically advanced diagnostic solutions to leverage unmet opportunities. For instance, in April 2019, Beckman Coulter Inc., a subsidiary of Danaher Corporation received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Early Sepsis Indicator. Earlier in May 2018, T2 Biosystems, Inc. also received the FDA approval for its T2Bacteria Panel, intended for the detection of specific sepsis-causing bacterial pathogens in human whole blood specimens. Thus, the rise in hospital-acquired infections and robust product development by the players are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.

Key Market Trends

Molecular Diagnostics Segment, by Technology, is Expected to grow the Fastest over the Forecast Period.

As per the Canadian Medical Association, in December 2020, the most common complications associated with COVID-19 were pneumonia, respiratory failure, kidney failure, and sepsis or systemic inflammation, consistent with other studies. The absolute risk of someone with COVID-19 having sepsis was estimated to be approximately 10.4%. Researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of the market.

Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics. Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in April 2019, GenMark Diagnostics, Inc. received the FDA clearance for its new panel assay, developed to detect gram-negative bacteria causing sepsis. The well-established healthcare infrastructure with high adoption of advanced diagnostic technologies and a rising awareness for early disease diagnosis are expected to drive the market’s growth.

North America is Expected to Hold Largest Share of the Market

COVID-19 has increased the overall risk of sepsis among the global population. The Global Sepsis Alliance stated that COVID-19 could cause sepsis, causing an overwhelming and life-threatening physiological response to an infection that can lead to organ damage and death. In the United States, one in three COVID-19 patients who dies in a hospital dies of sepsis. Owing to this high susceptibility to the disease in this region, the market is expected to grow in the future.

North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the CDC statistics in 2018, sepsis affects more than a million Americans every year and leads to 15% to 30% deaths in the United States. Furthermore, the number of sepsis cases is rising every year in the country due to factors, such as the rise in the geriatric population, infections that are incurable by antibiotics, and higher risks of the disease among people who have undergone an organ transplant. The National Institutes of Health supports many studies that are focused on sepsis, which evaluate various potential treatments for the disease. CDC launched the ‘Get Ahead of Sepsis’, which is an educational initiative to protect Americans from the effect of sepsis. This initiative calls on healthcare professionals to educate patients, prevent infections, identify and diagnose sepsis at an early stage, and start sepsis treatment fast. Emerging technologies linked with an enhanced understanding of the immature and developing neonatal immune system responses to early infection provide an opportunity to develop critically needed biomarkers to improve early identi?cation in this high-risk population. So, the increasing prevalence of sepsis and government initiatives may augment the growth of the market studied.

Competitive Landscape

The market studied is moderately consolidated owing to the presence of a few key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, Immunexpress Inc., Diasorin, Response Biomedical Corp., T2 Biosystems, Inc., and Thermo Fisher Scientific.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Apheresis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • $ 4250
  • October 2021
  • 140 pages

The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026. The ...

  • World
  • Healthcare
  • Blood Supply
  • Industry analysis
  • Chronic Disease Prevalence
  • Mortality Rate


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on